Adverse events (AEs) during the double-blind phase in the safety population; possibly, probably or definitely related to treatment
| Adverse event | Placebo (n=213) | Enterosgel (n=214) |
| Nausea | 8 (3.8%) (1 s, 2 mo, 5 m)* | 8 (3.7%) (2 mo, 6 m) |
| Abdominal pain | 4 (1.9%) (2 mo, 2 m) | 3 (1.4%) (1 mo, 2 m) |
| Bloating | 3 (1.4%) (2 mo, 1 m) | 6 (2.8%) (3 mo, 3 m) |
| Constipation | 2 (0.9%) (1 s, 1 m) | 2 (0.9%) (1 s, 1 m) |
| Headache | 2 (0.9%) (2 m) | 2 (0.9%) (1 s,1 m) |
| Dry mouth | 2 (0.9%) (1 mo, 1 m) | 1 (0.5%) (1 m) |
| Backpain | 0 (0%) | 2 (0.9%) (1 s,1 mo) |
| Loss of appetite | 0 (0%) | 2 (0.9%) (2 m) |
AE listed in descending order of frequency in the placebo group. The AEs listed were reported in two or more cases in either treatment group.
*AE severity; s=severe, mo=moderate, m=mild.